Samsung Bioepis Unveils Adalloce Prescription Data... Confirms Improved Quality of Life

Two Sets of Patient Prescription Data Presented at KCR 2026

"Post-Marketing Study Reconfirms Safety"

Samsung Bioepis presented real-world prescription data for Adalloce (ingredient name: adalimumab), its autoimmune disease treatment, at the Korean College of Rheumatology International Congress (KCR 2026).

Exterior view of Samsung Bioepis headquarters. Samsung Bioepis

The company announced on the 18th that it participated in KCR 2026, held from May 14 to 16 at the Conrad Hotel in Yeouido, Seoul, and presented two research findings related to the efficacy and safety of Adalloce.

The first study was an observational study involving 488 patients with rheumatoid arthritis and ankylosing spondylitis who were prescribed Adalloce. After 52 weeks of follow-up, the EQ-5D-5L score, an indicator of health-related quality of life (HRQoL), increased by an average of 0.09 points compared to baseline. The EQ-VAS score, in which patients self-assess their health status, improved by 11.9 points.

The second was a post-marketing surveillance (PMS) study involving 303 patients across all approved indications for Adalloce. The incidence of adverse events was 29.7%, and the incidence of serious adverse events was 2.6%. The safety profile was consistent with previous clinical trial results.

Data were also presented showing that patients who switched from conventional adalimumab formulations to Adalloce maintained similar disease activity scores, indicating stable disease control even after switching to the biosimilar.

Jihoon Gil, Executive Director at Samsung Bioepis, stated, "It is significant that the presentation of our research results at a prestigious international congress has confirmed the potential of our product to contribute to improved treatment and quality of life for patients in Korea."

This content was produced with the assistance of AI translation services.